Archived Page
The information on this page is archived and provided for reference purposes only. It was current when it was produced, but may now be out-of-date. Persons having difficulty accessing this information may contact kcl@nei.nih.gov for assistance. For reliable, current information on this and other topics, we recommend that you visit the National Eye Institute website index.
National Institutes of Health
National Eye Institute
National Eye Institute
(301) 496-5248
neinews@nei.nih.gov
B-roll and photos available
Patient recruitment has begun on a clinical trial to find out if laser treatment decreases vision loss for people who may be at risk for severe age-related macular degeneration (AMD).
AMD is a common eye disease of the macula, a tiny area in the retina that helps produce sharp, central vision required for “straight ahead” activities such as reading, sewing, and driving. A person with AMD - the leading cause of severe visual impairment in Americans 60 years of age and older - loses this clear, central vision. An estimated 1.7 million Americans have AMD.
The clinical trial, called the Complications of Age-Related Macular Degeneration Prevention Trial (CAPT), is designed to assess the safety and effectiveness of low intensity laser treatment. Researchers hope to determine if low intensity laser treatment might prevent disease progression and loss of vision in people who are at risk for severe AMD. The CAPT will enroll a total of 1000 patients in 23 clinical centers across the United States during an 18-month period. The trial will last at least five years and is sponsored by the National Eye Institute (NEI), part of the Federal government’s National Institutes of Health.
“As ‘baby boomers’ age and a higher percentage of Americans reach age 60, AMD will become an even more serious medical issue,” said Dr. Carl Kupfer, director of the NEI. “The prevalence of AMD is expected to rise to 6.3 million by the year 2030, when even greater percentages of our population will have turned 60.”
All patients in the trial will have one eye treated with the laser and one eye not treated. The treatment is performed quickly and causes little, if any, discomfort. Both eyes will be carefully monitored throughout the trial to evaluate any eye or vision problems and determine the effects of the laser treatment. There is a small chance that the new treatment could increase the risk of vision loss. Any important information gained from this study will be shared with all CAPT patients, doctors, and the public as soon as it becomes available.
To be eligible for the study, patients must meet all of the following criteria:
- Age 50 or older.
- Large drusen, or yellow deposits, in the retinas of both eyes. These deposits can be viewed only by an eye care professional through a dilated eye exam.
- Vision of 20/40 or better in each eye.
- No other eye disease affecting vision.
- Available for five years of follow-up.
- No previous laser treatment to the retina.
Those who are interested in participating in the trial and want more information should check with their eye care professional to see if they meet all the study criteria listed above. A booklet listing study centers can be obtained from the CAPT Coordinating Center at 3535 Market Street, Suite 700, Philadelphia, PA, 19104-3309. Information also is available on the CAPT web site at http://www.med.upenn.edu/cpob/studies/documents/MOP_July_2000.EP.pdf, or on the NEI’s web site at http://www.nei.nih.gov/neitrials/static/study70.asp. A list of study centers is attached.
|
CAPT Clinical Centers
|
|
|---|---|
|
Arizona Donald W. Park, M.D. Retinal Consultants of Arizona, Ltd. 560 West Brown Road, Suite 2004 Mesa, AZ 85201 Contact: Jennifer Blaisdell Telephone: (602) 402-0409 Fax: (602) 833-6209 Donald W. Park, M.D. Retinal Consultants of Arizona, Ltd. 10615 West Thunderbird Boulevard Suite D-500 Sun City, AZ 85351 Contact: Jennifer Blaisdell Telephone: (602) 402-0409 Fax: (602) 833-6209 California Florida Maryland Massachusetts Michigan Minnesota Missouri Pennsylvania Texas Wisconsin |
Georgia Paul Sternberg, Jr., M.D. Emory Eye Center Emory University School of Medicine 1365-B Clifton Road, 4th Floor, Rm. B4625 Atlanta, GA 30322 Contact: Ann Ervin, M.P.H. Telephone: (404) 778-2423 Fax: (404) 778-5128 Illinois Iowa Kentucky North Carolina New Jersey Ohio Oregon Photograph Reading Center NEI Representative |
Resource Centers
Chairman’s Office
Stuart L. Fine, M.D.
Scheie Eye Institute
Department of Ophthalmology
Univ. of Pennsylvania School of Medicine
51 N. 39th Street
Philadelphia, PA 19104
Telephone: (215) 662-8142
Coordinating Center
Maureen G. Maguire, Ph.D., Director
CAPT Coordinating Center
3535 Market Street, Suite 700
Philadelphia, PA 19104-3309
Telephone: (215) 615-1500
Fax: (215) 615-1531
News Blurb
NEI leads the federal government’s research on the visual system and eye diseases. NEI supports basic and clinical science programs that result in the development of sight-saving treatments. For more information, visit http://www.nei.nih.gov.
About the National Institutes of Health (NIH): NIH, the nation’s medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov/.
NIH…Turning Discovery Into Health®